Content about Specialty pharmacy

February 13, 2014

Janssen Biotech announced that the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy.

HORSHAM, Pa. — Janssen Biotech on Wednesday announced the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Imbruvica was first approved in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Both indications are based on an overall response rate. An improvement in survival or disease-related symptoms has not been established.

February 13, 2014

Teva Pharmaceutical Industries announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

February 11, 2014

The Generic Pharmaceutical Association announced its support of Georgia SB 370, introduced by pharmacist and Sen. Buddy Carter, R-Ga. District 1, because it will allow unimpeded patient access to interchangeable biologics.

WASHINGTON — The Generic Pharmaceutical Association on Tuesday announced its support of Georgia SB 370, introduced by pharmacist and Sen. Buddy Carter, R-Ga. District 1,  because it will allow unimpeded patient access to interchangeable biologics. The bill mirrors current pharmacy practice for interchangeable generic substitution language, and is aligned with Food and Drug Administration definitions, the association noted.

February 11, 2014

The Pharmacy Benefit Management Institute recently released its Specialty Drug Benefit Report, sponsored by Walgreens Specialty Pharmacy.

PLANO, Texas — The Pharmacy Benefit Management Institute recently released its Specialty Drug Benefit Report, sponsored by Walgreens Specialty Pharmacy. The 2014 edition highlights trends important to specialty pharmacy, including emerging cost-control strategies and challenges affecting benefit design and patient care. 

February 11, 2014

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists’ training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise, the retailer announced Tuesday.

DEERFIELD, Ill. — In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists’ training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise, the retailer announced Tuesday.

February 10, 2014

Women who take aspirin daily may reduce their risk of ovarian cancer by 20%, according to a study by scientists at the National Cancer Institute, part of the National Institutes of Health.

ROCKVILLE, Md. — Women who take aspirin daily may reduce their risk of ovarian cancer by 20%, according to a study by scientists at the National Cancer Institute, part of the National Institutes of Health. 

The study was published Feb. 6 in the Journal of the National Cancer Institute.

February 7, 2014

A new and possibly transformative technology for rapidly diagnosing and evaluating patients based on their specific genetic profile may soon begin appearing at retail pharmacies and clinics, giving pharmacists and clinicians another tool for advancing patient health outcomes and their own practice capabilities.

A new and possibly transformative technology for rapidly diagnosing and evaluating patients based on their specific genetic profile may soon begin appearing at retail pharmacies and clinics, giving pharmacists and clinicians another tool for advancing patient health outcomes and their own practice capabilities.

Dr. Anita Goel, M.D., Ph.D.

February 7, 2014

Selecting a doctor can be a frustrating process filled with too many unknowns, especially in today’s evolving landscape.

Selecting a doctor can be a frustrating process filled with too many unknowns, especially in today’s evolving landscape. Looking to help patients take the guesswork out of finding the ideal doctor, Vitals has developed online tools at Vitals.com to give patients visibility into quality, cost and availability.

February 6, 2014

Diplomat on Wednesday released its second episode in partnership with Pharmacy Podcast.

FLINT, Mich. — Diplomat on Wednesday released its second episode in partnership with Pharmacy Podcast. The new installment discusses the role of patient advocacy within the specialty pharmacy field. Diplomat’s manager of patient advocacy, Brenda Hawkes, joins Pharmacy Podcast’s Todd Eury for this conversation. 

February 5, 2014

CVS Caremark was awarded the 2014 Rx Benefit Innovation Award by the Pharmacy Benefit Management Institute on Tuesday, the company reported.

WOONSOCKET, R.I. — CVS Caremark was awarded the 2014 Rx Benefit Innovation Award by the Pharmacy Benefit Management Institute on Tuesday, the company reported. The award recognizes the company's new Specialty Connect program, which was developed by CVS Caremark to improve access, quality of care and convenience for specialty pharmacy patients.

February 4, 2014

Cornerstone Therapeutics, a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, on Monday announced that its stockholders have approved, at a special stockholder meeting, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.

CARY, N.C. — Cornerstone Therapeutics, a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, on Monday announced that its stockholders have approved, at a special stockholder meeting, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.

February 4, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated. 

The Accelerating Medicines Partnership — an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA — aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease. 

January 31, 2014

Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.

DUBLIN — Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 

January 31, 2014

Avella Specialty Pharmacy on Thursday named Rebecca Shanahan CEO. Shanahan brings more than two decades of successful leadership experience in the healthcare sector, as well as five years of service on Avella’s board of directors, to her new role.

PHOENIX — Avella Specialty Pharmacy on Thursday named Rebecca Shanahan CEO. Shanahan brings more than two decades of successful leadership experience in the healthcare sector, as well as five years of service on Avella’s board of directors, to her new role. 

January 31, 2014

The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week.

LONDON — The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week. 

January 31, 2014

Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:

January 30, 2014

The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning.

DUBLIN, Ohio — The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning. Revenue totaled $22.2 billion. The loss of the Walgreens contract totaled $5 billion. 

But Cardinal Health is bullish regarding its future. Cardinal Health increased its outlook for the next six months, raising its non-GAAP EPS range to $3.75 to $3.85. 

January 30, 2014

A new web platform has gone live from Diplomat, the nation’s largest independent specialty pharmacy reported.

FLINT, Mich. — A new web platform has gone live from Diplomat, the nation’s largest independent specialty pharmacy reported Thursday. On Jan. 29 the company revealed a completely redesigned site that is "mobile-friendly, easy to use and primed for upcoming changes."

January 30, 2014

Diplomat Pharmacy on Thursday announced that it will be partnering with The Whiting, Flint’s premier performing arts venue on bringing new entertainment opportunities to the area through the Gen X Concert Series.

FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it will be partnering with The Whiting, Flint’s premier performing arts venue on bringing new entertainment opportunities to the area through the Gen X Concert Series. Performers featured will be targeted to “Generation X," or those born in the early 1960s through the early 1980s.

In addition to the concert series, the partnership also will bring entertainment to Diplomat’s corporate headquarters. The Whiting will present local performers during select lunch periods for employees to enjoy.

January 29, 2014

Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report.

PHILADELPHIA — Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report released Tuesday. 

January 29, 2014

Teva announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL form.

JERUSALEM — Teva Pharmaceutical Industries on Tuesday announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL. Daily Copaxone in 20mg/mL dosage will continue to be available.  

Copaxone is administered to patients with relapsing forms of multiple sclerosis. The new formulation will allow for a less frequent dosing regimen.

January 28, 2014

Hamacher Resource Group has announced that is offering its workshop, How to Grow Sales Within Independent Pharmacy, again on March 6 at its headquarters in Waukesha, Wis.

WAUKESHA, Wis. — Hamacher Resource Group has announced that is offering its workshop, How to Grow Sales Within Independent Pharmacy, again on March 6 at its headquarters in Waukesha, Wis.

January 27, 2014

ScriptCycle, a technology company that serves pharmacies and patients, will launch its comprehensive cash solutions for retail pharmacies at the NACDS Regional Conference in February.

ASHEVILLE, N.C. — ScriptCycle, a technology company that serves pharmacies and patients, will launch its comprehensive cash solutions for retail pharmacies at the NACDS Regional Conference in February. The products aim to help pharmacies address challenges related to their cash prescription business, the company said.

ScriptCycle said its business model has produced average per-store savings of $7,000 to $12,000 per year.

January 27, 2014

The National Institutes of Health have awarded a University of Rhode Island pharmacy professor a $1.3 million grant to further study a new class of inorganic nanoparticles that target primary cancer and help control the disease’s spread and recurrence.



KINGSTON, R.I. — The National Institutes of Health have awarded a University of Rhode Island pharmacy professor a $1.3 million grant to further study a new class of inorganic nanoparticles that target primary cancer and help control the disease’s spread and recurrence.